Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States

Journal of Medical Economics

Volumn 18, Issue 6, 2015, Pages 420-432

  Foos, Volker ^a   Varol, Nebibe ^b   Curtis, Bradley H ^b   Boye, Kristina S ^b   Grant, David ^a   Palmer, James L ^a   McEwan, Phil ^c  

^a IQVIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Episode costs; Health economic evaluation; Hypoglycemia; Medical resources; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ARTICLE; COST UTILITY ANALYSIS; ECONOMIC ASPECT; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PRODUCTIVITY; QUALITY OF LIFE; RESOURCE ALLOCATION; SELF CARE; UNITED STATES; COST OF ILLNESS; DIABETES MELLITUS; ECONOMICS; EPIDEMIOLOGY; HEALTH SERVICE; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; UTILIZATION;

COST OF ILLNESS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; HYPOGLYCEMIA; MODELS, ECONOMETRIC; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84935916009     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1006730     Document Type: Article

References (37)

1. American Diabetes Association. Standards of medical care in diabetes 2011. Diabetes Care 2011;34(1 Suppl):11-61
2. Cryer PE. Hypoglycemia: Still the limiting factor in the glycemic management of diabetes. Endocr Pract 2008;14:750-6
3. Marrett E, Radican L, Davies MJ, et al. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study. BMC Res Notes 2011;4:251
4. ACCORD Study Group, Gerstein HC, Miller ME, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-28
5. UK Hypoglycaemia Study Group. Risk of hypoglycemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
6. Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
7. Tahrani A, Barnett AH, Brod M, et al. Global survey finds three quarters of patients experience hypoglycemia on insulin analogue causing dose irregularities and increased blood-glucose monitoring. Poster number 222 presented at: 48th EASD Annual Meeting; October 1-5, 2012; Berlin, Germany
8. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):5-26
9. McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE Diabetes Model. Value Health 2014;17:714-24
10. Jo? nsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with type 2 diabetes in Sweden. Value Health 2006;9:193-8
11. Cobden D, Lee WC, Balu S, et al. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy 2007;27:948-62
12. Bullano MF, Fisher MD, Grochulski WD, et al. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Am J Health Syst Pharm 2006;63:2473-82
13. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population-based study of health service resource use. Diabetes Care 2003;26:1176-80
14. Curkendall SM, Zhang B, Oh KS, et al. Incidence and cost of hypoglycemia among patients with type 2 diabetes in the United States: Analysis of a health insurance database. J Clin Outcome Manag 2011;18:455-62
15. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data. Clin Ther 2006;28:1712-25
16. Fabunmi R, Nielsen LL, Quimbo R, et al. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin 2009;25:777-86
17. Lundkvist J, Berne C, Bolinder B, et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005;6:197-202
18. Quilliam BJ, Simeone JC, Ozbay AB, et al. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care 2011;17:673-80
19. Williams SA, Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011;91:363-70
20. Hammer M, Lammert M, Mej?a?s SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009;12: 281-90
21. Davis RE, Morrissey M, Peters JR, et al. Impact of hypoglycemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005;21:1477-83
22. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994;17:697-703
23. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
24. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care 2013;36:1384-95
25. U.S. Department of Labor. Bureau of Labor Statistics. U.S. consumer price index-all urban consumers. Medical care 1982-84. http://data.bls.gov/cgibin/surveymost?cu. Accessed August 2014
26. Hay JW, Smeeding J, Carroll NV, et al. Good research practices for measuring drug costs in cost effectiveness analyses: Issues and recommendations: The ISPOR Drug Cost Task Force Report-Part I. Value Health 2010; 13:3-7
27. US Bureau of Labor Statistics. http://www.bls.gov. Accessed June 15, 2013
28. Werner CA. U.S. Department of Commerce, Economics and Statistics Administration U.S. Census Bureau. The Older Population: 2010. 2011. http://www.census.gov/prod/cen2010/briefs/c2010br-09.pdf. Accessed September 17, 2014
29. Howden LM. U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau. Age and Sex Composition: 2010, 2010 Census Briefs. 2011. http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf. Accessed September 17, 2014
30. U.S. Census Bureau. State & county quick facts. http://quickfacts.census.gov/qfd/states/00000.html. Accessed September 17, 2014
31. WorldatWork. Paid time off programs and practices: A survey of WorldatWork members, May 2010. http://www.worldatwork.org/waw/adimLink?id? 38913. Accessed September 17, 2014
32. Leiter LA, Yale JF, Chiasson JL, et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005;29:186-92
33. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
34. Yeaw J, Lee WC, Aagren M, et al. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes. J Manag Care Pharm 2012;18:21-32
35. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57: 3169-76
36. Saleh M, Grunberger G. Hypoglycemia: An excuse for poor glycemic control? Clin Diabetes 2001;19:161-7
37. Heaton A, Martin S, Brelje T. The economic effect of hypoglycemia in a health plan. Manag Care Interface 2003;16:23-7